🇯🇵 日本語 🇺🇸 English
3,803 companies 7,082 AI summaries 5,914 risk analyses 2,848 growth scores Register free — watchlist & alerts →
EDINET 4151 Positive Risk Analyzed 📈 Growth 7/10

Kyowa Kirin Co.,Ltd.

Semi-Annual Report - 104th Term(2026/01/01 - 2026/12/31) ／ 2026-08-03 15:32

Covers EDINET statutory filings (TDNET timely disclosures / earnings flashes are not included).

EarningsGuidance UpVolumeNew ProductNew MarketR&D
AI Summary 2026-08-03 15:35

H1 FY2026: Revenue +14.3% (¥2,636M), Core OP +79.6% (¥661M), Net income +87.6% (¥306M). Global strategy products (North America, EMEA) drove growth; tech income increased. FX tailwind +¥126M. Orchard divested, Amgen contract terminated.

KEY POINTS
  • Revenue YoY +14.3% (¥2,307M → ¥2,636M), including FX benefit of ¥126M
  • Core OP +79.6% (¥368M → ¥661M), boosted by R&D cost reduction
  • Net income +87.6% (¥163M → ¥306M); global strategy brands (Crysvita, Poteligeo) solid
  • Operating CF surged +104.2% (¥398M → ¥813M); cash position up ¥463M to ¥2,651M
  • Japan revenue -5.9% (¥592M → ¥549M) due to pricing cuts, G-CSF biosimilar competition, product transitions
📊 Revenue
Revenue +14.3% (¥2,307M → ¥2,636M), including FX tailwind of ¥126M
💰 Operating profit
Core OP +79.6% (¥368M → ¥661M)
🔮 Outlook
Full-year guidance not stated. Focused on delivering Life-changing value in bone/mineral, blood cancers, rare diseases under Story for Vision 2030.
📈 Growth outlook 📈 Growth 7/10
Steady mid-single digit growth expected. Global strategy products (Crysvita +19.1%, Poteligeo +19.9%) and new KOMZIFTI launch drive expansion. Gene therapy pipeline (OTL-203, OTL-200, OTL-201) advancing. Japan market pressure from pricing headwinds.
Growth drivers
  • Crysvita (XLH) geographic expansion in NA/EMEA; new syringe formulation launched
  • Global rare disease product expansion (Poteligeo, Libmeldy/Lenmeldy across geographies)
  • KOMZIFTI (ziftomenib) FDA approval & US launch Nov 2025; multi-indication trials ongoing
  • Advanced modality pipeline (hematopoietic stem cell gene therapy) clinical progress
Risk and growth scores and tags are AI-generated estimates from analyzing the disclosure. They are not guarantees of fact, nor investment advice or recommendations. Make investment decisions at your own discretion.
⚠️ Extracted Risk Factors
CategoryDescriptionScoreNew
Market Risk Japanese pricing pressure: H1 Japan sales -5.9% driven by April 2025/2026 price cuts and biosimilar competition. Future pricing reforms pose downside risk to domestic revenue. 6/10
Competitive Intensity Risk Zarista (G-CSF) biosimilar competition caused -21.9% sales decline. Risk of similar competitive pressure cascading to other mature products. 6/10
Foreign Exchange Risk Foreign operations account for 63.6% of sales; H1 benefited from weak yen (+¥126M). Yen strength poses material headwind to earnings translation. 6/10
Technology / Pipeline Risk Majority of pipeline in early/mid-stage development (Phase I/II). Ziftomenib, OTL-203 require multi-year development; delays or failures would impact future growth. 5/10
M&A Risk Orchard Therapeutics wound down (Jan 2026), removed from consolidation. High reliance on external partnerships (Kura, QED, Amgen termination Jan 2026). Partnership changes create revenue uncertainty. 5/10
Regulatory Risk Pharmaceutical approvals depend on regulatory authorities (FDA, EMA, PMDA). Unexpected denials, conditional approvals, or delayed timelines could impact market launches. 5/10
Customer Concentration Risk Kirin Holdings controls 55.16% of voting rights. Shift in parental strategy or investment priorities could impact corporate direction and drug development allocation. 4/10
Litigation Risk Pharma industry faces product liability, patent disputes, and adverse event litigation. Risk escalates with expanding product portfolio and clinical trial volumes. 4/10
6/10 Market Risk
Japanese pricing pressure: H1 Japan sales -5.9% driven by April 2025/2026 price cuts and biosimilar competition. Future pricing reforms pose downside risk to domestic revenue.
6/10 Competitive Intensity Risk
Zarista (G-CSF) biosimilar competition caused -21.9% sales decline. Risk of similar competitive pressure cascading to other mature products.
6/10 Foreign Exchange Risk
Foreign operations account for 63.6% of sales; H1 benefited from weak yen (+¥126M). Yen strength poses material headwind to earnings translation.
5/10 Technology / Pipeline Risk
Majority of pipeline in early/mid-stage development (Phase I/II). Ziftomenib, OTL-203 require multi-year development; delays or failures would impact future growth.
5/10 M&A Risk
Orchard Therapeutics wound down (Jan 2026), removed from consolidation. High reliance on external partnerships (Kura, QED, Amgen termination Jan 2026). Partnership changes create revenue uncertainty.
5/10 Regulatory Risk
Pharmaceutical approvals depend on regulatory authorities (FDA, EMA, PMDA). Unexpected denials, conditional approvals, or delayed timelines could impact market launches.
4/10 Customer Concentration Risk
Kirin Holdings controls 55.16% of voting rights. Shift in parental strategy or investment priorities could impact corporate direction and drug development allocation.
4/10 Litigation Risk
Pharma industry faces product liability, patent disputes, and adverse event litigation. Risk escalates with expanding product portfolio and clinical trial volumes.
X LinkedIn Threads Bluesky Facebook
Track Japanese disclosures with JSIGNAL

AI summaries, risk & growth analysis, watchlist alerts and a screener for every Japanese listed company.

Start free — 30-day trial Login